ESC 365 - Cardiovascular primary prevention risk factors in a nationwide survey, ABC (atrial fibrillation, high blood pressure and high cholesterol) risk factors in the LIPIDOGRAM2015 study

ESC Premium Access

Cardiovascular primary prevention risk factors in a nationwide survey, ABC (atrial fibrillation, high blood pressure and high cholesterol) risk factors in the LIPIDOGRAM2015 study

Session: Risk Factors and Prevention ePosters

Topic: Cardiovascular Risk Assessment

Speaker: Mr O. Greaves (Liverpool, GB)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Mr Owain Greaves

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)

0 follower

224 more presentations in this session

High risk characteristics in patients with hypertrophic cardiomiyopathy for predicting cardiovascular events

Speaker: Doctor B. Keskin (Istanbul, TR)

Cardiac biomarkers as prognosticators among SARS-CoV-19 patients in a tertiary hospital in Philippines

Speaker: Doctor R. Ong (Makati, PH)

Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndromes; final data of the nationwide cross-sectional CardioRisk project

Speaker: Doctor A. Bendary (Benha, EG)

SF-12 Physical and Mental Health Scales predict cardiovascular events after hospitalization

Speaker: Mr R. Gascuena (Leganes, ES)

Comparison of traditional versus artificial intelligence based coronary artery disease risk prediction scores in young patients with acute coronary syndrome

Speaker: Doctor S. Vohra (Lucknow, IN)

Access the full session

Risk Factors and Prevention ePosters

Speakers: Mr O. Greaves, Doctor B. Keskin, Doctor R. Ong, Doctor A. Bendary, Mr R. Gascuena...

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

ESC Premium Access

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

27 August 2021

ESC Premium Access

Cardiovascular benefits outweigh risks in patients with atrial fibrillation in REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial)

27 August 2021

ESC Premium Access

Potential cardiovascular risk reduction with evolocumab in the real world: a simulation in patients with a history of myocardial infarction from the HEYMANS register

27 August 2021

ESC 365 is supported by